MRTX
Mirati Therapeutics Inc
A biotech company that developed Krazati (adagrasib), a pill for certain non-small cell lung cancers driven by a genetic mutation called KRAS G12C. Mirati started in 1995 under the name MethylGene and later renamed itself after the Italian word for "targeted," a nod to its precision-oncology focus; it was acquired by Bristol Myers Squibb in 2024. One of the hardest proteins in medicine to drug, KRAS was long called "undruggable," and Mirati's medicine helped crack it open.
CUSIP: 60468T105HealthcareUS1 holder
Total Value
$328.0K
Total Shares
7.2K
Net Share Change
+7.2K
Activity
1 buying
Investor
Value
Shares
Weight
Change
